| P/E (FY) | — | Sales (TTM) | $8,000 |
| Earnings (TTM) | -$33.6M | ROE | −170.00% |
| Net Margin | −401812.50% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −91.03% |
| Market Cap | $130.9M | Trading Days | 875 |
| 52W High | 8.54 |
| 52W Low | 2.29 |
| % Off High | −65.79% |
| YTD | −33.03% | 1Y | −13.86% |
| 3Y | −86.21% | Since incept. (ann.) | −19.16% |
Operating And Reportable Segments 100%
| Ann. Volatility (1Y) | 80.79% | Ann. Volatility (3Y) | 99.69% |
| Sharpe (1Y) | 0.24 | Sharpe (3Y) | −0.19 |
| Max Drawdown (1Y) | −72.09% | Max Drawdown (3Y) | −94.60% |
| Beta (3Y, vs SPY) | 1.53 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PMN | ProMIS Neurosciences Inc. | $130.2M | — |
| UNCY | Unicycive Therapeutics, Inc. | $131.9M | — |
| MIST | Milestone Pharmaceuticals Inc. | $133.2M | — |
| NGEN | NERVGEN PHARMA CORP. | $128.2M | — |
| PEPG | PepGen Inc. | $126.6M | — |
| HURA | TuHURA Biosciences, Inc./NV | $135.6M | — |
| AARD | Aardvark Therapeutics, Inc. | $140.1M | — |
| ADCT | ADC Therapeutics SA | $141.2M | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $120.7M | — |
| CNTN | Canton Strategic Holdings, Inc. | $142.4M | — |
| ANIX | Anixa Biosciences Inc |
| $119.8M |
| — |
| MSLE | Satellos Bioscience Inc. | $146.2M | — |
